A UICC-led initiative pioneering access solutions for cancer medicines
The work of the ATOM Coalition, led by UICC, extends beyond short term solutions: addressing longstanding barriers in healthcare systems that limit patient access to quality, timely cancer medicines, including registration of medicines in country, supply chain management, and the availability of pathology and diagnostic infrastructure.
The ATOM Coalition will work alongside UICC members in ATOM Coalition target countries to support country governments through locally relevant training, skill development and infrastructure strengthening aimed at strengthening the country’s capacity to receive and use cancer medicines. By leveraging the resources and expertise within the Coalition and engaging with UICC members, the capacity strengthening programme will focus on key four critical areas to respond to country-specific needs:
A key focus area for the ATOM Coalition will be providing support to generic, biosimilar and originator manufacturers to register and supply quality-assured essential cancer medicines at affordable prices in ATOM Coalition target countries. The initial focus will be on increasing access to five generic essential medicines listed on the ATOM Coalition target medicines list for breast cancer and adjuvant therapies.
Through various channels, the ATOM Coalition will focus on securing an increasing number of patented medicines and new medicines in the pipeline from biopharmaceutical companies over time. This will include exploring opportunities to extend donations programmes to ATOM Coalition target countries, discounted pricing options and voluntary licensing pathways through the Medicines Patent Pool. The initial focus will be on securing five patented medicines on the WHO EML for other priority cancers, and two patented medicines not currently on the WHO EML but recommended to pursue a voluntary license.
With guidance from the Medicines Expert Advisory group, the ATOM Coalition has established a target list of priority generic, biosimilar, and patented medicines currently on the WHO EML, with a focus on cancers with the highest incidence and mortality in LLMICs: breast, lung, colorectal, prostate, cervical and childhood cancers.
Download the complete list
In its first phase, the ATOM Coalition will concentrate on strengthening access to essential oncology medicines in 46 LLMICs. In parallel, capacity building activities will commence in a subset of 10 of these 46 LLMICs based on analysis of a range of readiness criteria. Criteria include:
the current presence of UICC member organisations
Angola, Benin, Côte d’Ivoire, Burundi, Cameroon, Ethiopia, Congo, Ghana, Guinea, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Senegal, Tanzania, Togo, Uganda, Zambia
Belize, Bolivia, El Salvador, Guatemala, Haiti, Honduras, Nicaragua
Georgia, Kosovo, Kyrgyz Rep., Tajikistan, Uzbekistan
Egypt, Morocco, Tunisia, Pakistan
South and South-East Asia
Bangladesh, Bhutan, India, Nepal, Sri Lanka, Indonesia
Cambodia, Lao, Mongolia, Papua New Guinea, Philippines
Be part of the UICC-led efforts to reduce suffering and deaths caused by cancer in low- and lower-middle income countries through improved access to and use of essential cancer medicines.
Get in touch